Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00766636 · ClinicalTrials.gov registry record · Phase 2

Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy

A Phase 2 study, sponsored by M.D. Anderson Cancer Center.

Terminated
Registry status
Phase 2
Development phase
5
Enrollment target

NCT00766636: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.

NCT00766636 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add start date to calendar (.ics) →

The verdict

NCT00766636, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.

TERMINATED
Registry status
Phase 2
Development phase
5 participants
Enrollment target

Study Summary

Primary Objective: To assess margin positive resection rate (R1 resection rate; defined as "tumor within 2 mm of surgical margin on final pathology report") in patients treated with preoperative chemotherapy (gemcitabine and erlotinib) with or without external-beam radiation therapy followed by pancreaticoduodenectomy for adenocarcinoma of the pancreatic head. Secondary Objectives: * To assess disease free survival * To assess overall survival * To assess patterns of local and distant failure

Primary Outcome

Difference in positive margin resection (R1) rate in patients who undergo surgery between the two treatment groups. Margin resection rate is defined as number of patients with R1 margin divided by the total number of patients who received surgery in that arm. Eligible patients will be equally (1:1 ratio) randomized to one of the two arms to receive either Gemcitabine and Erlotinib or Gemcitabine and Erlotinib and radiation as preoperative therapy. Surgery to be performed approximately 4 weeks af

Interventions

  • RADIATION Radiation Therapy
  • DRUG Gemcitabine
  • PROCEDURE Surgery
  • DRUG Erlotinib

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2008-09
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

Why NCT00766636 stopped before completion

NCT00766636 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 4 interventions - of which Radiation Therapy is the first listed.

NCT00766636 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00766636 about?

NCT00766636 is a clinical study titled "Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy". Primary Objective: To assess margin positive resection rate (R1 resection rate; defined as "tumor within 2 mm of surgical margin on final pathology report") in patients treated with preoperative chemotherapy (gemcitabine and erlotinib) with or without external-beam radiation therapy followed by pan...

What is the current status of trial NCT00766636?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2008-09.

What interventions are being tested in trial NCT00766636?

The interventions under investigation include: Radiation Therapy (RADIATION), Gemcitabine (DRUG), Surgery (PROCEDURE), Erlotinib (DRUG).

Who is sponsoring clinical trial NCT00766636?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00766636's enrollment target sits among peer trials

5 2000th of 2000 the lowest of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00766636, the US trial registry maintained by the National Library of Medicine. NCT00766636 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.